Navigation Links
Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
Date:6/3/2009

COPENHAGEN, June 3 /PRNewswire/ -- Santaris Pharma and Copenhagen Institute of Technology, Aalborg University, Denmark, announced today that Director of microRNA, Santaris Pharma, Sakari Kauppinen, has been appointed Adjunct Professor in RNA Biology at Copenhagen Institute of Technology. The appointment has immediate effect and will last five years. Sakari Kauppinen, who will continue his in current role as Director of MicroRNA Research at Santaris Pharma, will give his inaugural lecture in August this year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

Sakari Kauppinen, Director of MicroRNA Research at Santaris Pharma said:

"I feel very honored to be appointed Adjunct Professor in RNA Biology at the Copenhagen Institute of Technology, Aalborg University. Close collaborations with academia are essential for Santaris Pharma's expanding microRNA therapeutics program, which aims at translating the basic knowledge about microRNAs in disease into development of novel medicines with the potential to improve human health. I am looking forward to interacting closely with Aalborg University, whose experience in working with the biotech industry is highly synergistic with our way of collaborating with academia."

Soren Tulstrup, CEO of Santaris Pharma said:

"We are thrilled that Sakari Kauppinen has received this important academic appointment. Sakari Kauppinen has helped bring Santaris Pharma to a leadership position worldwide within the exciting new scientific field of microRNA, and I am sure he will contribute significantly to the university in his future additional capacity as Adjunct Professor."

Lene Lange, Professor, Dr. Scient. Vice Dean for the Faculties of Engineering, Science and Medicine, Aalborg University said:

"Sakari Kauppinen is superbly qua
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
2. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
3. 2009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60% Despite Current Recession
4. Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
5. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
7. ViroPharma to Present at Two June Healthcare Conferences
8. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
11. Pharmacyclics Files Registration Statement for Rights Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 The World Molecular ... appointment of Lisa Baird as Executive Director. Baird ... 2013. The WMIS vision is to encompass ... understand and effectively treat diseases in the developed and ... was established in 2011 by integrating the Academy of ...
(Date:5/17/2013)... Topricin Pain Relief and Healing Cream, ... among nationally recommended over-the-counter (OTC) health products 2012 ... News" Health in collaboration with "Pharmacy Times." ... Pharmacists Recommended designation” in the “Topical Analgesics” category, ... is the only homeopathic formula to earn that ...
(Date:5/17/2013)... rejection occurs when the transplant recipient,s immune system identifies ... It was previously thought that T cells, the immune ... molecules known as chemokines in order to migrate to ... Journal of Clinical Investigation , Fadi Lakkis and colleagues ... that chemokine stimulation of T cells is not required ...
(Date:5/17/2013)... UK (PRWEB) May 17, 2013 The ... Photonics21 at the association’s recent annual meeting ... including EC Vice-President Neelie Kroes, who called the action ... sectors, and a stimulant to European innovation.” , The ... structure of the new Photonics PPP at its 29 ...
Breaking Biology Technology:WMIS Appoints Lisa Baird as Next Executive Director 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3
... Alfacell Corporation (OTC Bulletin Board: ACEL) today reported ... U.S. Food and Drug Administration (FDA) to discuss the ... ONCONASE rolling New Drug Application (NDA) for the treatment ... pre-NDA meeting, the FDA provided guidance to the company ...
... PUBLISHED BY UNIVERSAL , NETTLETON, Miss., Jan. 27 ... that certain unauthorized inaccurate information is being published ... website, potentially other websites and publications, and an ... company has found errors in statements concerning the ...
... Scheduled for Tuesday, February 3, 2009 SAN DIEGO, Jan. ... ) announced today that the Company will report its ... Nasdaq market closes on Tuesday, February 3, 2009. Neurocrine ... to discuss its financial results and provide a Company ...
Cached Biology Technology:Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results 2
(Date:5/17/2013)... a group of proteins in the brain responsible for ... target that could increase cell survival. , The discovery, ... and published in the EMBO journal with ... new therapies for stroke and other brain diseases. , ... which identified a protein, known as SUMO, responsible for ...
(Date:5/17/2013)... An international team of scientists ... and cell movement inside a living frog embryo in ... new method to advance biological research and the search ... University and the Karlsruher Institut fr Technologie in Germany, ... U.S. Department of Energy,s Argonne National Laboratory, released the ...
(Date:5/16/2013)... ancient shorelines to predict the stability of today,s largest ice ... from three million years ago, for example when Earth ... be evidence of a high sea level due to ice ... scientists to think that if the world,s largest ice sheets ... same in our modern, progressively warming world. , However, ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2New X-ray method shows how frog embryos could help thwart disease 2World's biggest ice sheets likely more stable than previously believed 2
... Technological University (NTU), and Israel,s number one university, ... new collaboration to jointly offer a Doctor of ... PhD degree programme is a university-wide agreement and ... Bioengineering. Significantly, the joint PhD degree will also ...
... the study and manipulation of human embryonic stem cells ... competition for a Hebrew University of Jerusalem researcher. ... Benvenisty of the Silberman Institute of Life Sciences was ... the Hebrew University of Jerusalem Board of Governors 73rd ...
... Guam,s territorial entomologist and Aubrey Moore, UOG extension entomologist, ... early June. Jackson was invited to assist in ... (Oryctes rhinoceros) population. This virus only infects rhino ... of the pest on other Pacific islands. The ...
Cached Biology News:NTU ramps up collaboration with Israel's top university 2NTU ramps up collaboration with Israel's top university 3Research on stem cells wins first prize for Hebrew University researcher 2Research on stem cells wins first prize for Hebrew University researcher 3Unusual rhino beetle behavior discovered 2